Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 145

Similar articles for PubMed (Select 24166835)


Role of TGF-β in a mouse model of high turnover renal osteodystrophy.

Liu S, Song W, Boulanger JH, Tang W, Sabbagh Y, Kelley B, Gotschall R, Ryan S, Phillips L, Malley K, Cao X, Xia TH, Zhen G, Cao X, Ling H, Dechow PC, Bellido TM, Ledbetter SR, Schiavi SC.

J Bone Miner Res. 2014;29(5):1141-57. doi: 10.1002/jbmr.2120.


Repression of osteocyte Wnt/β-catenin signaling is an early event in the progression of renal osteodystrophy.

Sabbagh Y, Graciolli FG, O'Brien S, Tang W, dos Reis LM, Ryan S, Phillips L, Boulanger J, Song W, Bracken C, Liu S, Ledbetter S, Dechow P, Canziani ME, Carvalho AB, Jorgetti V, Moyses RM, Schiavi SC.

J Bone Miner Res. 2012 Aug;27(8):1757-72. doi: 10.1002/jbmr.1630.


Advanced glycation end products suppress lysyl oxidase and induce bone collagen degradation in a rat model of renal osteodystrophy.

Aoki C, Uto K, Honda K, Kato Y, Oda H.

Lab Invest. 2013 Nov;93(11):1170-83. doi: 10.1038/labinvest.2013.105. Epub 2013 Aug 26.


Inhibition of TGF-β signaling by 1D11 antibody treatment increases bone mass and quality in vivo.

Edwards JR, Nyman JS, Lwin ST, Moore MM, Esparza J, O'Quinn EC, Hart AJ, Biswas S, Patil CA, Lonning S, Mahadevan-Jansen A, Mundy GR.

J Bone Miner Res. 2010 Nov;25(11):2419-26. doi: 10.1002/jbmr.139.


Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats.

Meng Y, Zhang H, Li Y, Li Q, Zuo L.

Bone. 2014 Jan;58:168-76. doi: 10.1016/j.bone.2013.10.010. Epub 2013 Oct 18.


TGF-β induces Wnt10b in osteoclasts from female mice to enhance coupling to osteoblasts.

Ota K, Quint P, Ruan M, Pederson L, Westendorf JJ, Khosla S, Oursler MJ.

Endocrinology. 2013 Oct;154(10):3745-52. doi: 10.1210/en.2013-1272. Epub 2013 Jul 16.


Treatment of a murine model of high-turnover renal osteodystrophy by exogenous BMP-7.

González EA, Lund RJ, Martin KJ, McCartney JE, Tondravi MM, Sampath TK, Hruska KA.

Kidney Int. 2002 Apr;61(4):1322-31.


Insulin-like growth factor system components in hyperparathyroidism and renal osteodystrophy.

Jehle PM, Ostertag A, Schulten K, Schulz W, Jehle DR, Stracke S, Fiedler R, Deuber HJ, Keller F, Boehm BO, Baylink DJ, Mohan S.

Kidney Int. 2000 Feb;57(2):423-36.


Inhibition of transforming growth factor-β restores endothelial thromboresistance in vein grafts.

Kapur NK, Bian C, Lin E, Deming CB, Sperry JL, Hansen BS, Kakouros N, Rade JJ.

J Vasc Surg. 2011 Oct;54(4):1117-1123.e1. doi: 10.1016/j.jvs.2011.04.037. Epub 2011 Jul 31.


Renal osteodystrophy: alpha-Heremans Schmid glycoprotein/fetuin-A, matrix GLA protein serum levels, and bone histomorphometry.

Coen G, Ballanti P, Balducci A, Grandi F, Manni M, Mantella D, Pierantozzi A, Ruggeri M, Sardella D, Sorbo G, Bonucci E.

Am J Kidney Dis. 2006 Jul;48(1):106-13.


Therapeutic role of TGF-beta-neutralizing antibody in mouse cyclosporin A nephropathy: morphologic improvement associated with functional preservation.

Ling H, Li X, Jha S, Wang W, Karetskaya L, Pratt B, Ledbetter S.

J Am Soc Nephrol. 2003 Feb;14(2):377-88.


Increased bone mass in mice after single injection of anti-receptor activator of nuclear factor-kappaB ligand-neutralizing antibody: evidence for bone anabolic effect of parathyroid hormone in mice with few osteoclasts.

Furuya Y, Mori K, Ninomiya T, Tomimori Y, Tanaka S, Takahashi N, Udagawa N, Uchida K, Yasuda H.

J Biol Chem. 2011 Oct 21;286(42):37023-31. doi: 10.1074/jbc.M111.246280. Epub 2011 Aug 23.


Down-regulation of human osteoblast PTH/PTHrP receptor mRNA in end-stage renal failure.

Picton ML, Moore PR, Mawer EB, Houghton D, Freemont AJ, Hutchison AJ, Gokal R, Hoyland JA.

Kidney Int. 2000 Oct;58(4):1440-9.


Cholesterol-sensing receptors, liver X receptor alpha and beta, have novel and distinct roles in osteoclast differentiation and activation.

Robertson KM, Norgård M, Windahl SH, Hultenby K, Ohlsson C, Andersson G, Gustafsson JA.

J Bone Miner Res. 2006 Aug;21(8):1276-87.


Neutralization of transforming growth factor-beta attenuates hypertension and prevents renal injury in uremic rats.

Lavoie P, Robitaille G, Agharazii M, Ledbetter S, Lebel M, Larivière R.

J Hypertens. 2005 Oct;23(10):1895-903.


Hyperactive transforming growth factor-β1 signaling potentiates skeletal defects in a neurofibromatosis type 1 mouse model.

Rhodes SD, Wu X, He Y, Chen S, Yang H, Staser KW, Wang J, Zhang P, Jiang C, Yokota H, Dong R, Peng X, Yang X, Murthy S, Azhar M, Mohammad KS, Xu M, Guise TA, Yang FC.

J Bone Miner Res. 2013 Dec;28(12):2476-89. doi: 10.1002/jbmr.1992.


Attenuated Wnt/β-catenin signalling mediates methotrexate chemotherapy-induced bone loss and marrow adiposity in rats.

Georgiou KR, King TJ, Scherer MA, Zhou H, Foster BK, Xian CJ.

Bone. 2012 Jun;50(6):1223-33. doi: 10.1016/j.bone.2012.03.027. Epub 2012 Mar 29.


A comparative study of the bone metabolic response to dried plum supplementation and PTH treatment in adult, osteopenic ovariectomized rat.

Smith BJ, Bu SY, Wang Y, Rendina E, Lim YF, Marlow D, Clarke SL, Cullen DM, Lucas EA.

Bone. 2014 Jan;58:151-9. doi: 10.1016/j.bone.2013.10.005. Epub 2013 Oct 11.


Pretreatment of bone with osteoclasts affects phenotypic expression of osteoblast-like cells.

Boyan BD, Schwartz Z, Lohmann CH, Sylvia VL, Cochran DL, Dean DD, Puzas JE.

J Orthop Res. 2003 Jul;21(4):638-47.


Transforming growth factor beta 1 induces CXCL16 and leukemia inhibitory factor expression in osteoclasts to modulate migration of osteoblast progenitors.

Ota K, Quint P, Weivoda MM, Ruan M, Pederson L, Westendorf JJ, Khosla S, Oursler MJ.

Bone. 2013 Nov;57(1):68-75. doi: 10.1016/j.bone.2013.07.023. Epub 2013 Jul 25.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk